BiotechTube
Field Medical

Field Medical

San Diego, United States· Est.
fieldmedicalinc.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $181.1M

Overview

Field Medical is an early-stage innovator in the rapidly growing pulsed field ablation (PFA) market for cardiac arrhythmias. The company is developing the FieldForce Ablation System and is actively conducting first-in-human clinical trials for both atrial fibrillation (AF) and ventricular tachycardia (VT). Led by CEO Dr. Mark Turco and founded by Dr. Steven Mickelsen, the company combines clinical expertise with engineering to create a potentially safer and more effective ablation technology. Field Medical is currently pre-revenue and is selectively engaging with strategic partners and investors to fund its development and clinical programs.

CardiologyCardiac Arrhythmias

Technology Platform

Proprietary pulsed field ablation (PFA) system (FieldForce™) using targeted, non-thermal electrical fields to selectively ablate cardiac tissue for the treatment of arrhythmias like atrial fibrillation and ventricular tachycardia.

Funding History

100
Total raised:$181.1M
Grant$913K
Grant$289K
Grant$315K
Grant$1.0M

Opportunities

Field Medical has the opportunity to establish a leadership position in pulsed field ablation for ventricular tachycardia, a significant unmet need with less competitive saturation than atrial fibrillation.
Success in its ongoing clinical trials could attract strategic partnership or acquisition interest from larger medtech companies looking to expand their electrophysiology portfolios.
The overall rapid growth of the PFA market provides a strong tailwind for a differentiated technology.

Risk Factors

The company faces intense competition from well-funded, large-cap medical device companies that have already launched or are developing PFA systems for atrial fibrillation.
Clinical failure or serious adverse events in its first-in-human trials would significantly devalue the company and threaten its viability.
As a pre-revenue startup, Field Medical is dependent on raising additional capital to fund operations and clinical studies, which carries inherent financing risk.

Competitive Landscape

The pulsed field ablation market is highly competitive, dominated by large players like Boston Scientific (FARAPULSE), Medtronic (PulseSelect), and Johnson & Johnson/Biosense Webster. Field Medical's strategy appears to be focusing on technological differentiation and targeting the complex ventricular tachycardia indication, which is less addressed by current first-generation PFA systems. Its success will depend on demonstrating clinical superiority or a unique safety profile in this niche.

More companies in Digital Health & Biotech SaaS →More companies in United States →